Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (41-50 of 182) with videos related to

Pageof 19
Sort By:
Advances in Experimental Medicine and Biology|September 10, 2013
Towards targeted therapy of chronic lymphocytic leukemiaCarsten U Niemann, Jade Jones, Adrian Wiestner
The New England Journal of Medicine|July 30, 2020
Ibrutinib for Chronic Lymphocytic Leukemia with <i>TP53</i> AlterationsInhye E Ahn, Xin Tian, Adrian Wiestner
Haematologica|March 2, 2016
Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibAndrew H Lipsky, Jay N Lozier, Adrian Wiestner
Hematology/Oncology Clinics of North America|April 9, 2013
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implicationsYair Herishanu, Ben-Zion Katz, Andrew Lipsky, et al.
Mabs|April 26, 2012
Targeting malignant B cells with an immunotoxin against ROR1Sivasubramanian Baskar, Adrian Wiestner, Wyndham H Wilson, et al.
Infectious Diseases in Clinical Practice (Baltimore, Md.)|December 6, 2016
Pneumocystis jirovecii Pneumonia in a Treatment-Naive Patient With Chronic Lymphocytic LeukemiaJeffrey R Strich, Theresa D Jerussi, Adrian Wiestner, et al.
Oncoimmunology|November 20, 2012
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?Margaret A Lindorfer, Adrian Wiestner, Clive S Zent, et al.
Blood|March 29, 2019
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLLInhye E Ahn, Neil Basumallik, Xin Tian, et al.
Blood|August 10, 2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinibInhye E Ahn, Theresa Jerussi, Mohammed Farooqui, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 6, 2003
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphomaGeorge Wright, Bruce Tan, Andreas Rosenwald, et al.
Pageof 19

Showing results (41-50 of 182) with videos related to

Sort By:
Pageof 19
Advances in Experimental Medicine and Biology|September 10, 2013
Towards targeted therapy of chronic lymphocytic leukemiaCarsten U Niemann, Jade Jones, Adrian Wiestner
The New England Journal of Medicine|July 30, 2020
Ibrutinib for Chronic Lymphocytic Leukemia with <i>TP53</i> AlterationsInhye E Ahn, Xin Tian, Adrian Wiestner
Haematologica|March 2, 2016
Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibAndrew H Lipsky, Jay N Lozier, Adrian Wiestner
Hematology/Oncology Clinics of North America|April 9, 2013
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implicationsYair Herishanu, Ben-Zion Katz, Andrew Lipsky, et al.
Mabs|April 26, 2012
Targeting malignant B cells with an immunotoxin against ROR1Sivasubramanian Baskar, Adrian Wiestner, Wyndham H Wilson, et al.
Infectious Diseases in Clinical Practice (Baltimore, Md.)|December 6, 2016
Pneumocystis jirovecii Pneumonia in a Treatment-Naive Patient With Chronic Lymphocytic LeukemiaJeffrey R Strich, Theresa D Jerussi, Adrian Wiestner, et al.
Oncoimmunology|November 20, 2012
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?Margaret A Lindorfer, Adrian Wiestner, Clive S Zent, et al.
Blood|March 29, 2019
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLLInhye E Ahn, Neil Basumallik, Xin Tian, et al.
Blood|August 10, 2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinibInhye E Ahn, Theresa Jerussi, Mohammed Farooqui, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 6, 2003
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphomaGeorge Wright, Bruce Tan, Andreas Rosenwald, et al.
Pageof 19